CN107373673A - 用于心脑血管病引起的失能半失能患者的全营养配方食品 - Google Patents
用于心脑血管病引起的失能半失能患者的全营养配方食品 Download PDFInfo
- Publication number
- CN107373673A CN107373673A CN201710726062.4A CN201710726062A CN107373673A CN 107373673 A CN107373673 A CN 107373673A CN 201710726062 A CN201710726062 A CN 201710726062A CN 107373673 A CN107373673 A CN 107373673A
- Authority
- CN
- China
- Prior art keywords
- disability
- cardiovascular
- patient
- oil
- cerebrovascular diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 42
- 230000035764 nutrition Effects 0.000 title claims abstract description 40
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 33
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 30
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 30
- 235000013305 food Nutrition 0.000 title claims abstract description 27
- 239000000843 powder Substances 0.000 claims abstract description 35
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 20
- 239000011707 mineral Substances 0.000 claims abstract description 20
- 235000021323 fish oil Nutrition 0.000 claims abstract description 14
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 13
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims abstract description 13
- 229920001353 Dextrin Polymers 0.000 claims abstract description 12
- 239000004375 Dextrin Substances 0.000 claims abstract description 12
- 239000002131 composite material Substances 0.000 claims abstract description 12
- 235000019425 dextrin Nutrition 0.000 claims abstract description 12
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960001231 choline Drugs 0.000 claims abstract description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004475 Arginine Substances 0.000 claims abstract description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019197 fats Nutrition 0.000 claims description 15
- 241000196324 Embryophyta Species 0.000 claims description 14
- 239000005913 Maltodextrin Substances 0.000 claims description 14
- 229920002774 Maltodextrin Polymers 0.000 claims description 14
- 229940035034 maltodextrin Drugs 0.000 claims description 14
- 235000014633 carbohydrates Nutrition 0.000 claims description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 10
- 239000008158 vegetable oil Substances 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 102000004407 Lactalbumin Human genes 0.000 claims description 5
- 108090000942 Lactalbumin Proteins 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 240000007594 Oryza sativa Species 0.000 claims description 5
- 235000007164 Oryza sativa Nutrition 0.000 claims description 5
- 235000019483 Peanut oil Nutrition 0.000 claims description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- 108010073771 Soybean Proteins Proteins 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 239000011651 chromium Substances 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 235000005687 corn oil Nutrition 0.000 claims description 5
- 239000002285 corn oil Substances 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 235000021388 linseed oil Nutrition 0.000 claims description 5
- 239000000944 linseed oil Substances 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 210000001161 mammalian embryo Anatomy 0.000 claims description 5
- 229910052750 molybdenum Inorganic materials 0.000 claims description 5
- 239000011733 molybdenum Substances 0.000 claims description 5
- 229940055726 pantothenic acid Drugs 0.000 claims description 5
- 235000019161 pantothenic acid Nutrition 0.000 claims description 5
- 239000011713 pantothenic acid Substances 0.000 claims description 5
- 239000000312 peanut oil Substances 0.000 claims description 5
- 239000011574 phosphorus Substances 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 235000009566 rice Nutrition 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- 235000019710 soybean protein Nutrition 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000011691 vitamin B1 Substances 0.000 claims description 5
- 239000011715 vitamin B12 Substances 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- DPRNENKPXAZQBI-UHFFFAOYSA-N alpha-Vitamin A Natural products OCC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C DPRNENKPXAZQBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003240 coconut oil Substances 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 102000004452 Arginase Human genes 0.000 claims description 3
- 108700024123 Arginases Proteins 0.000 claims description 3
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 229940125782 compound 2 Drugs 0.000 claims 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 abstract description 11
- 230000001071 malnutrition Effects 0.000 abstract description 11
- 235000000824 malnutrition Nutrition 0.000 abstract description 11
- 208000015380 nutritional deficiency disease Diseases 0.000 abstract description 11
- 230000007423 decrease Effects 0.000 abstract description 8
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 230000003247 decreasing effect Effects 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 230000004083 survival effect Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 14
- 230000006870 function Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 208000021090 palsy Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 235000020795 whole food diet Nutrition 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000012898 Olfaction disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010034018 Parosmia Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- OBODKGDXEIUEIH-DAWLFQHYSA-N all-trans-3-hydroxyretinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CC(O)CC1(C)C OBODKGDXEIUEIH-DAWLFQHYSA-N 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于全营养技术领域，提出了用于心脑血管病引起的失能半失能患者的全营养配方食品，由下列重量份的组分组成：碳水化合物40～60g，蛋白粉15～28g，HMB0.5～0.75g，谷氨酰胺1.5～5g，精氨酸0～4g，亮氨酸0.5～1g，抗性糊精2～6g，低聚木糖0.17～0.4g，棉子糖0.75～2.5g，低聚果糖1.25～2g，植物脂肪8～13g，中链甘油三酯2.5～4g，鱼油粉0～0.2g，胆碱0.09～0.5g，复合矿物质2～4g，复合维生素0.5～1.5g。本发明解决了心脑血管病引起的失能半失能患者的蛋白质能量代谢障碍、营养不良导致患者治疗耐受力下降、治疗效果下降、生活质量下降、生存时间缩短、并发症增加，营养不良的问题。
Description
技术领域
本发明属于全营养技术领域，涉及一种用于心脑血管病引起的失能半失能 患者的全营养配方食品。
背景技术
第六次人口普查显示，60岁及以上人口占全国总人口的13.26％，比2000 年人口普查上升2.93个百分点，其中65岁及以上人口占8.87％，比2000年上 升1.91个百分点。全国老龄办发布《第四次中国城乡老年人生活状况抽样调查 成果》报告显示，有18.3％的老年人为失能、半失能状态，总数达4063万人。 神经***慢性疾病，营养问题已逐渐引起重视。由心血管疾病引起的失能和半 失能患者往往因为神经功能受损、吞咽障碍、意识障碍、心理因素等多方面原 因导致摄食减少，胃肠动力学、胃肠血液动力学和神经内分泌功能改变，影响 营养物质的消化和吸收。其营养不良风险和营养不良发生率非常高。另一方面，失能老年人膳食搭配一般较为简单，营养结构不全面，再加之食物摄人量也相 对较少，摄人的蛋白质数量和质量都相对较差，也增加了营养不良的风险。
心脑血管疾病是心血管和脑血管的疾病统称，泛指由于高脂血症、血液黏 稠、动脉粥样硬化、高血压等所导致的心脏、大脑及全身组织发生的缺血性或 出血性疾病。心脑血管疾病是一种严重威胁人类，特别是50岁以上中老年人健 康的常见病，即使应用目前最先进、完善的治疗手段，仍可有50％以上的脑血 管意外幸存者生活不能完全自理。目前，我国心脑血管疾病患者已经超过2.7亿 人，我国每年死于心脑血管疾病近300万人，占我国每年总死亡病因的51％。 心脑血管疾病使老年患者丧失劳动力、生活不能自理、致残，而且是老年患者 死亡的主要元凶，已经对现代社会构成严重的威胁。心脑血管疾病是危害人类健康的第一大杀手，不但对人们的生命健康造成重大危胁，而且给社会带来沉 重的经济负担。
失能是个体健康测量的重要指标，指一个人在日常生活中主要活动能力或 生活能力的丧失或受限。目前常用以下标准：定义吃饭、穿衣、上下床、上厕 所、室内走动、洗澡6项指标，如果有两项以下做不到，则定义为轻度失能老 人，如果2-3项做不到，则定义为中度失能老人，5-6项做不到的为重度失能老 人。轻度失能患者的日常活动受限不大，生活上基本能自理，也称为半失能。 而心脑血管疾病患者绝大部分为失能半失能人群。
患者失能后因为神经功能受损、进食障碍、意识障碍、运动减少等多方面 原因导致摄食减少，引起机体脱水、电解质紊乱、缺氧及维生素和矿物质缺乏， 长时间会造成蛋白质能量代谢障碍、营养不良。营养不良不仅导致患者治疗耐 受力下降、治疗效果下降、生活质量下降、生存时间缩短、并发症增加，而且 给患者家庭、单位、国家带来了巨大的社会经济负担。
在一般情况下，老年人合成代谢过程小于分解代谢过程，随着日常活动的 减少，基础代谢不断下降。有研究显示60岁人的基础代谢大约较20岁时下降 16％，70岁时则减少25％，合成代谢小于分解代谢，从而致使细胞功能下降。 老年人的脑功能、肝功能、肾功能、心功能、和胃肠功能都随年龄增高而有所 下降。从30岁起肾脏细胞每10年大约下降10％，肾小球滤过率降低；糖耐量 下降；肺细胞弹性下降；胃肠分泌的消化液减少，胃肠蠕动减弱；以及机体的 免疫功能随年龄而下降，故老年人对于营养不良的耐受要比年轻人差，日常生 活中各种生理、病理因素均可使老年人缺乏足够的营养，威胁身体健康。需要 通过膳食调节和合理的营养满足不同老年人对多种营养素的需求，防止因营养 不良所致疾病的危害。
老年人由于生物和生理变化，可能存在营养不良风险，并且老年人可能本 身并发某些潜在基础疾病。由于肌肉质量减少而脂肪百分比增加导致机体组成 和营养需求的变化。基础代谢率降低从而降低能量需求。并伴有视觉、嗅觉障 碍、食物选择的限制、咀嚼困难度的增加。当慢性或急性疾病引起的代谢改变， 增加营养需求时，如果食物摄入量差或营养物质的吸收减少，容易继发营养衰 竭。因此，中老年人的营养问题更为复杂，需谨慎对待。
由于老年人身体重要器官功能贮备明显减少，体内环境的稳定性逐渐降低 以及各种基础疾病或急性疾病影响，营养不良发生率较高。维持老年人的营养 良好状况意义重大，充足的能量和营养摄入对于老年人保持营养状况、预防营 养不良至关重要。营养不良与老年人较差的日常活动能力和身体功能密切相关。
一项调查，296例≥65岁需要照顾(即失能半失能)的老年人，其中57％ 的老人有营养不良的风险，12％存在营养不良。营养状况良好的老人其身体功 能状态亦显著优于营养状况差者。
患心脑血管病的老年人营养风险发生率较高。住院超过3周的老年重度脑 卒病人中，高达56.3％的患者曾发生营养不良。急性期脑卒中患者有16％～35％ 发生营养不良，卒中恢复阶段营养不良的发生率为32％～49％。营养不良可导致 卒中并发症发生率高。营养不良的风险是卒中发生6个月时患者的死亡率、住 院时间和住院花费的独立预测因素。
发明内容
本发明提出一种用于心脑血管病引起的失能半失能患者的全营养配方食 品，解决了现有技术中的上述问题。
本发明的技术方案是这样实现的：
用于心脑血管病引起的失能半失能患者的全营养配方食品，由下列重量份 的组分组成：
碳水化合物40～60g，蛋白粉15～28g，HMB0.5～0.75g，谷氨酰胺1.5～5g， 精氨酸0～4g，亮氨酸0.5～1g，抗性糊精2～6g，低聚木糖0.17～0.4g，棉子糖 0.75～2.5g，低聚果糖1.25～2g，植物脂肪8～13g，中链甘油三酯2.5～4g，鱼油粉 0～0.2g，胆碱0.09～0.5g，复合矿物质2～4g，复合维生素0.5～1.5g，
其中，碳水化合物为麦芽糊精与酶解米粉任意比例混合物，蛋白粉选自乳 清蛋白和/或大豆分离蛋白，HMB以Ca-HMB的形式添加。
作为进一步的技术方案，由下列重量份的组分组成：碳水化合物50g，蛋白 粉22g，HMB0.62g，谷氨酰胺3.2g，精氨酸2g，亮氨酸0.8g，抗性糊精4g，低 聚木糖0.3g，棉子糖1.5g，低聚果糖1.6g，植物脂肪10.5g，中链甘油三酯3.2g， 鱼油粉0.1g，胆碱0.3g，复合矿物质3g，复合维生素1g。
作为进一步的技术方案，所述抗性糊精与低聚木糖、棉籽糖、低聚果糖的 总量为7～9g。
作为进一步的技术方案，所述蛋白粉的蛋白含量为80％。
作为进一步的技术方案，所述植物脂肪经过预包埋处理，包埋剂为麦芽糊 精，且植物油与麦芽糊精比例为1:1.2～1.5，植物油来源于大豆油、亚麻油、椰 子油、玉米油、棕榈油、花生油、胚芽油中的一种或几种。
作为进一步的技术方案，所述鱼油粉的有效成分大于等于40％。
作为进一步的技术方案，每100mg复合矿物质预混料包括：钙10～14mg， 钠12～16mg，钾16～25mg，铜0.018～0.022mg，镁4～6mg，铁0.15～0.24mg，锌 0.08～0.23mg，碘1.1～1.7μg，磷6～17mg，锰5～25mg，钼0.9～2μg，硒0.5～1μg， 铬0.42～1μg。
作为进一步的技术方案，每100mg矿物质预混料包括：维生素A21～35μg， 维生素D0.45～0.8μg，维生素E0.48～0.8mg，维生素K2～3μg，维生素 B10.04～0.06mg，维生素B20.04～0.06mg，维生素B60.05～0.06mg，维生素 B120.08～0.1μg，维生素C3.4～10mg，烟酰胺0.44～0.81mg，叶酸13.5～30μg， 泛酸0.17～0.22mg，生物素1.2～2μg。
本发明使用原理及有益效果为：
本发明中的全营养配方食品很好的解决了心脑血管病引起的失能半失能患 者的蛋白质能量代谢障碍、营养不良导致患者治疗耐受力下降、治疗效果下降、 生活质量下降、生存时间缩短、并发症增加，营养不良的问题，HMB为β-羟基 -β-甲基丁酸，本发明创新性的将HMB增加至全营养食品用于解决心脑血管病 引起的失能半失能患者，通过其与碳水化合物、蛋白粉、HMB、谷氨酰胺、精 氨酸、亮氨酸、抗性糊精、低聚木糖、棉子糖、低聚果糖、植物脂肪、中链甘 油三酯、鱼油粉、胆碱、复合矿物质、复合维生素合适的配比添加，通过全营养食用，增加其耐受力和行动力，从而使其自主实现营养状况的提升，很好的 提高了解决失能半失能患者的代谢问题和营养问题的技术水平。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描 述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中 的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其 他实施例，都属于本发明保护的范围。
实施例1
本发明提出的用于心脑血管病引起的失能半失能患者的全营养配方食品， 由下列重量份的组分组成：碳水化合物40g，蛋白粉15g，HMB0.5g，谷氨酰胺 1.5g，亮氨酸0.5g，抗性糊精2g，低聚木糖0.17，棉子糖0.75g，低聚果糖1.25g， 植物脂肪8g，中链甘油三酯2.5g，胆碱0.09g，复合矿物质2g，复合维生素0.5g。 其中，碳水化合物为麦芽糊精与酶解米粉任意比例混合物，蛋白粉选自乳清蛋 白和/或大豆分离蛋白，HMB以Ca-HMB的形式添加。(抗性糊精与低聚木糖、 棉籽糖、低聚果糖的总量为7～9g为较好的比例)。所述蛋白粉的蛋白含量为80％。 所述植物脂肪经过预包埋处理，包埋剂为麦芽糊精，且植物油与麦芽糊精比例 为1:1.2，植物油来源于大豆油、亚麻油、椰子油、玉米油、棕榈油、花生油、 胚芽油中的一种或几种。所述鱼油粉的有效成分大于等于40％。每100mg复合 矿物质预混料包括：钙10mg，钠12mg，钾16mg，铜0.018mg，镁4mg，铁0.15mg， 锌0.08mg，碘1.1μg，磷6mg，锰5mg，钼0.9μg，硒0.5μg，铬0.42μg。每 100mg矿物质预混料包括：维生素A21μg，维生素D0.45μg，维生素E0.48mg， 维生素K2μg，维生素B10.04mg，维生素B20.04mg，维生素B6 0.05mg，维生 素B120.08μg，维生素C3.4mg，烟酰胺0.44mg，叶酸13.5μg，泛酸0.17mg， 生物素1.2μg。
实施例2
本发明提出的用于心脑血管病引起的失能半失能患者的全营养配方食品， 由下列重量份的组分组成：碳水化合物60g，蛋白粉28g，HMB0.75g，谷氨酰 胺5g，精氨酸4g，亮氨酸1g，抗性糊精6g，低聚木糖0.4g，棉子糖2.5g，低 聚果糖2g，植物脂肪13g，中链甘油三酯4g，鱼油粉0.2g，胆碱0.5g，复合矿 物质4g，复合维生素1.5g。其中，碳水化合物为麦芽糊精与酶解米粉任意比例 混合物，蛋白粉选自乳清蛋白和/或大豆分离蛋白，HMB以Ca-HMB的形式添 加。所述蛋白粉的蛋白含量为80％。所述植物脂肪经过预包埋处理，包埋剂为 麦芽糊精，且植物油与麦芽糊精比例为1:1.5，植物油来源于大豆油、亚麻油、 椰子油、玉米油、棕榈油、花生油、胚芽油中的一种或几种。所述鱼油粉的有 效成分大于等于40％。每100mg复合矿物质预混料包括：钙14mg，钠16mg， 钾25mg，铜0.022mg，镁6mg，铁0.24mg，锌0.23mg，碘1.7μg，磷17mg， 锰25mg，钼2μg，硒1μg，铬1μg。每100mg矿物质预混料包括：维生素 A35μg，维生素D0.8μg，维生素E0.8mg，维生素K3μg，维生素B10.06mg， 维生素B20.06mg，维生素B60.06mg，维生素B120.1μg，维生素C10mg，烟酰 胺0.81mg，叶酸30μg，泛酸0.22mg，生物素2μg。
实施例3
本发明提出的用于心脑血管病引起的失能半失能患者的全营养配方食品， 由下列重量份的组分组成：碳水化合物50g，蛋白粉22g，HMB0.62g，谷氨酰 胺3.2g，精氨酸2g，亮氨酸0.8g，抗性糊精4g，低聚木糖0.3g，棉子糖1.5g， 低聚果糖1.6g，植物脂肪10.5g，中链甘油三酯3.2g，鱼油粉0.1g，胆碱0.3g， 复合矿物质3g，复合维生素1g。其中，碳水化合物为麦芽糊精与酶解米粉任意 比例混合物，蛋白粉选自乳清蛋白和/或大豆分离蛋白，HMB以Ca-HMB的形 式添加。所述蛋白粉的蛋白含量为80％。所述植物脂肪经过预包埋处理，包埋剂为麦芽糊精，且植物油与麦芽糊精比例为1:1.35，植物油来源于大豆油、亚麻 油、椰子油、玉米油、棕榈油、花生油、胚芽油中的一种或几种。所述鱼油粉 的有效成分大于等于40％。每100mg复合矿物质预混料包括：钙12mg，钠14mg， 钾20.5mg，铜0.02mg，镁5mg，铁0.2mg，锌0.15mg，碘1.4μg，磷11.5mg， 锰15mg，钼14.5μg，硒0.75μg，铬0.7μg。每100mg矿物质预混料包括：维 生素A28μg，维生素D0.67μg，维生素E0.65mg，维生素K2.5μg，维生素B10.05mg，维生素B20.05mg，维生素B60.055mg，维生素B120.09μg，维生素 C6.7mg，烟酰胺0.62mg，叶酸22.5μg，泛酸0.2mg，生物素1.6μg。
将上述3实施例全营养配方食品为日餐进行临床实验，以下为临床数据：
患者李某某，男，80岁。冠心病，陈旧心肌梗死，心力衰竭，心功能IV级， 心律失常，室性期前收，心房颤动，高血压3级，极高危，腹水，脑梗死，双 侧颈动脉狭窄，重度营养不良，经口摄入不足。食用实施例1全营养配方食品 为日餐，如下表1为使用前后部分指标：
表1实施例1临床数据
患者崔某某，女，62岁。左侧基底节区脑出血脑肿胀；吸入性肺炎；高血 压3级，极高危；应激性溃疡。食用实施例2全营养配方食品为日餐，如下表2 为使用前后部分指标：
表2实施例2临床数据
患者徐某某，女，79岁。脑梗死，高血压3级极高危；贫血；Ⅱ型呼吸衰 竭右侧胸腔积液；骨质疏松；双侧额颞部硬膜下积液；颈动脉斑块；双下肢动 脉斑块；左侧股动脉狭窄；肺部感染。食用实施例3全营养配方食品为日餐， 如下表3为使用前后部分指标：
从三个实施例可以看出患者通过食用本发明的全营养配方食品，血清总蛋 白、血清白蛋白、血清血红蛋白均有回升，因此本发明能够补充消耗的蛋白质， 有效减缓机体蛋白质进行性分解进程，能够阻止或纠正低蛋白血症的发生。患 者大量瘦体组织分解，因此出现负氮平衡，因此蛋白质分解的主要终产物是尿 素的变化可直接反应机体蛋白质代谢情况，当机体处于应激状态时，蛋白质分 解增加，尿素合成增多，总淋巴细胞是机体免疫应答功能的重要细胞成分，是 评价细胞免疫功能的较可靠指标，服用后，从各表可以看出三位患者淋巴细胞 上升，因此机体免疫力得到了提高。
因此本发明中的全营养配方食品很好的解决了心脑血管病引起的失能半失 能患者的蛋白质能量代谢障碍、营养不良导致患者治疗耐受力下降、治疗效果 下降、生活质量下降、生存时间缩短、并发症增加，营养不良的问题，HMB为 β-羟基-β-甲基丁酸，本发明创新性的将HMB增加至全营养食品用于解决心脑血 管病引起的失能半失能患者，通过其与碳水化合物、蛋白粉、HMB、谷氨酰胺、 精氨酸、亮氨酸、抗性糊精、低聚木糖、棉子糖、低聚果糖、植物脂肪、中链 甘油三酯、鱼油粉、胆碱、复合矿物质、复合维生素合适的配比添加，通过全 营养食用，增加其耐受力和行动力，从而使其自主实现营养状况的提升，很好 的提高了解决失能半失能的代谢问题和营养问题的水平。
以上所述仅为本发明的较佳实施例而已，并不用以限制本发明，凡在本发 明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发 明的保护范围之内。
Claims (8)
1.用于心脑血管病引起的失能半失能患者的全营养配方食品，其特征在于，由下列重量份的组分组成：
碳水化合物40～60g，蛋白粉15～28g，HMB0.5～0.75g，谷氨酰胺1.5～5g，精氨酸0～4g，亮氨酸0.5～1g，抗性糊精2～6g，低聚木糖0.17～0.4g，棉子糖0.75～2.5g，低聚果糖1.25～2g，植物脂肪8～13g，中链甘油三酯2.5～4g，鱼油粉0～0.2g，胆碱0.09～0.5g，复合矿物质2～4g，复合维生素0.5～1.5g，
其中，碳水化合物为麦芽糊精与酶解米粉任意比例混合物，蛋白粉选自乳清蛋白和/或大豆分离蛋白，HMB以Ca-HMB的形式添加。
2.根据权利要1所述的用于心脑血管病引起的失能半失能患者的全营养配方食品，其特征在于，由下列重量份的组分组成：
碳水化合物50g，蛋白粉22g，HMB0.62g，谷氨酰胺3.2g，精氨酸2g，亮氨酸0.8g，抗性糊精4g，低聚木糖0.3g，棉子糖1.5g，低聚果糖1.6g，植物脂肪10.5g，中链甘油三酯3.2g，鱼油粉0.1g，胆碱0.3g，复合矿物质3g，复合维生素1g。
3.根据权利要1所述的用于心脑血管病引起的失能半失能患者的全营养配方食品，其特征在于，所述抗性糊精与低聚木糖、棉籽糖、低聚果糖的总量为7～9g。
4.根据权利要1所述的用于心脑血管病引起的失能半失能患者的全营养配方食品，其特征在于，所述蛋白粉的蛋白含量为80％。
5.根据权利要1所述的用于心脑血管病引起的失能半失能患者的全营养配方食品，其特征在于，所述植物脂肪经过预包埋处理，包埋剂为麦芽糊精，且植物油与麦芽糊精比例为1:1.2～1.5，植物油来源于大豆油、亚麻油、椰子油、玉米油、棕榈油、花生油、胚芽油中的一种或几种。
6.根据权利要1所述的用于心脑血管病引起的失能半失能患者的全营养配方食品，其特征在于，所述鱼油粉的有效成分大于等于40％。
7.根据权利要1所述的用于心脑血管病引起的失能半失能患者的全营养配方食品，其特征在于，每100mg复合矿物质预混料包括：钙10～14mg，钠12～16mg，钾16～25mg，铜0.018～0.022mg，镁4～6mg，铁0.15～0.24mg，锌0.08～0.23mg，碘1.1～1.7μg，磷6～17mg，锰5～25mg，钼0.9～2μg，硒0.5～1μg，铬0.42～1μg。
8.据权利要1所述的用于心脑血管病引起的失能半失能患者的全营养配方食品，其特征在于，每100mg矿物质预混料包括：维生素A21～35μg，维生素D0.45～0.8μg，维生素E0.48～0.8mg，维生素K2～3μg，维生素B1 0.04～0.06mg，维生素B2 0.04～0.06mg，维生素B60.05～0.06mg，维生素B12 0.08～0.1μg，维生素C3.4～10mg，烟酰胺0.44～0.81mg，叶酸13.5～30μg，泛酸0.17～0.22mg，生物素1.2～2μg。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710726062.4A CN107373673A (zh) | 2017-08-22 | 2017-08-22 | 用于心脑血管病引起的失能半失能患者的全营养配方食品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710726062.4A CN107373673A (zh) | 2017-08-22 | 2017-08-22 | 用于心脑血管病引起的失能半失能患者的全营养配方食品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107373673A true CN107373673A (zh) | 2017-11-24 |
Family
ID=60353975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710726062.4A Pending CN107373673A (zh) | 2017-08-22 | 2017-08-22 | 用于心脑血管病引起的失能半失能患者的全营养配方食品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107373673A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201800000722A1 (it) * | 2018-01-11 | 2019-07-11 | Marco Alvise Formiconi | Composizione alimentare a basso contenuto di carboidrati formulata con Destrine Resistenti ed utilizzata per la preparazione di prodotti alimentari ad ampio spettro di utilizzo anche medicale |
| CN111227243A (zh) * | 2020-02-28 | 2020-06-05 | 昆明医科大学第一附属医院 | 一种具有特殊医学用途配方的食品 |
| CN113812552A (zh) * | 2021-09-01 | 2021-12-21 | 江南大学 | 一种具有预防动脉粥样硬化功能的全营养固体饮料 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101278736A (zh) * | 2008-03-28 | 2008-10-08 | 西安力邦制药有限公司 | 一种适合亚洲人群营养支持的均衡肠内全营养制剂 |
| CN103330215A (zh) * | 2013-07-11 | 2013-10-02 | 西安力邦临床营养有限公司 | 一种适用于肿瘤患者的营养配方食品 |
| CN104082739A (zh) * | 2014-06-24 | 2014-10-08 | 广州纽健生物科技有限公司 | 一种全营养半消化特殊医学用途配方食品及其制备方法 |
| CN104286841A (zh) * | 2014-08-29 | 2015-01-21 | 韶关邦世迪健康实业有限公司 | 一种用于脑卒中患者的全营养制剂 |
| CN105707878A (zh) * | 2016-04-19 | 2016-06-29 | 北京希康宁生物技术有限责任公司 | 一种肿瘤全营养配方食品 |
| CN106072573A (zh) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | 一种适用于老年肌肉衰减症食用的特膳食品 |
| CN106377756A (zh) * | 2015-08-03 | 2017-02-08 | 安徽华明制药有限公司 | 一种重症脑梗死患者的肠内营养乳剂 |
-
2017
- 2017-08-22 CN CN201710726062.4A patent/CN107373673A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101278736A (zh) * | 2008-03-28 | 2008-10-08 | 西安力邦制药有限公司 | 一种适合亚洲人群营养支持的均衡肠内全营养制剂 |
| CN103330215A (zh) * | 2013-07-11 | 2013-10-02 | 西安力邦临床营养有限公司 | 一种适用于肿瘤患者的营养配方食品 |
| CN104082739A (zh) * | 2014-06-24 | 2014-10-08 | 广州纽健生物科技有限公司 | 一种全营养半消化特殊医学用途配方食品及其制备方法 |
| CN104286841A (zh) * | 2014-08-29 | 2015-01-21 | 韶关邦世迪健康实业有限公司 | 一种用于脑卒中患者的全营养制剂 |
| CN106377756A (zh) * | 2015-08-03 | 2017-02-08 | 安徽华明制药有限公司 | 一种重症脑梗死患者的肠内营养乳剂 |
| CN105707878A (zh) * | 2016-04-19 | 2016-06-29 | 北京希康宁生物技术有限责任公司 | 一种肿瘤全营养配方食品 |
| CN106072573A (zh) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | 一种适用于老年肌肉衰减症食用的特膳食品 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201800000722A1 (it) * | 2018-01-11 | 2019-07-11 | Marco Alvise Formiconi | Composizione alimentare a basso contenuto di carboidrati formulata con Destrine Resistenti ed utilizzata per la preparazione di prodotti alimentari ad ampio spettro di utilizzo anche medicale |
| CN111227243A (zh) * | 2020-02-28 | 2020-06-05 | 昆明医科大学第一附属医院 | 一种具有特殊医学用途配方的食品 |
| CN113812552A (zh) * | 2021-09-01 | 2021-12-21 | 江南大学 | 一种具有预防动脉粥样硬化功能的全营养固体饮料 |
| CN113812552B (zh) * | 2021-09-01 | 2023-12-26 | 江南大学 | 一种全营养固体饮料 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cashman | Calcium intake, calcium bioavailability and bone health | |
| CN100355420C (zh) | 富含亮氨酸的营养组合物 | |
| TW492867B (en) | Nutrition for persons infected with human immunodeficiency virus | |
| CN102077936B (zh) | 一种糖尿病患者专用的海洋特膳食品 | |
| JP5315996B2 (ja) | 総合経腸栄養組成物 | |
| CN102077934B (zh) | 一种高血压患者专用的海洋特膳食品 | |
| CN104286849A (zh) | 一种糖尿病专用型肠内营养多聚合剂 | |
| CN109846029A (zh) | 一种用于癌症患者的肠内营养剂 | |
| JP2012197293A (ja) | 総合経腸栄養組成物 | |
| CN109588709A (zh) | 一种预防老年肌肉衰减的复合蛋白粉及制备方法 | |
| CN107373673A (zh) | 用于心脑血管病引起的失能半失能患者的全营养配方食品 | |
| WO2008014674A1 (fr) | Sel de potassium comestible nutritionnel et de soin ayant un large champ d'application | |
| CN105942506A (zh) | 一种适于肝病患者的特殊医学用途配方食品 | |
| CN104286841A (zh) | 一种用于脑卒中患者的全营养制剂 | |
| JP2008247748A (ja) | 透析患者用栄養組成物 | |
| Margetts et al. | A randomized control trial of a vegetarian diet in the treatment of mild hypertension | |
| WO2009135959A1 (es) | Producto alimenticio para la nutrición por vía enteral u oral del paciente diabético | |
| CN101091571A (zh) | 全日营养肽 | |
| CN102077943B (zh) | 一种记忆力衰退者专用的海洋特膳食品 | |
| BRPI1007037A2 (pt) | formulação multivitamínica/mineral para combater os efeitos de estresse ambiental ; melhorar a imunidade e melhorar energia e ao mesmo tempo combater deficiências vitamínicas e minerais sem os efeitos colaterais negativos de um suplemento nutricional de megadoses | |
| Cruz et al. | Diabetes Nutrition and Complications Trial: Trends in nutritional pattern between 1993 and 2000 and targets of diabetes treatment in a sample of Spanish people with diabetes | |
| CN103621871A (zh) | 一种复合氨基酸保健品及其制备方法 | |
| CN105166901A (zh) | 一种透析患者用营养组合物 | |
| US20090017136A1 (en) | Formulation to prevent and treat fibromyalgia, depression and other muscle and nervous system disorders | |
| AU2021253451A1 (en) | Vitality dietary supplement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180409 Address after: 050000 Hebei city of Shijiazhuang province Donggang Road No. 89 Applicant after: The First Hospital of Hebei Medical University Applicant after: Hebei Jian Yuan clinical nutrition Co., Ltd. Address before: 050000 111 Qinling Mountains Avenue, Shijiazhuang high tech Zone, Hebei 225 Applicant before: Hebei Jian Yuan clinical nutrition Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210223 Address after: 050000 No.89 Donggang Road, Shijiazhuang City, Hebei Province Applicant after: THE FIRST HOSPITAL OF HEBEI MEDICAL University Address before: 050000 No.89 Donggang Road, Shijiazhuang City, Hebei Province Applicant before: THE FIRST HOSPITAL OF HEBEI MEDICAL University Applicant before: HEBEI JIANSU CLINIC NUTRITION Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171124 |
|
| RJ01 | Rejection of invention patent application after publication |